Bolt Biotherapeutics, Inc. (BOLT) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2025. Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, specifically focusing on its Boltbody® ISAC platform and myeloid biology expertise. The company operates as a single segment and is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. As of November 5, 2025, there were 1,919,441 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Collaboration Revenue | $2.17 million | $1.14 million | $5.20 million | $7.69 million |
| Total Operating Expenses | $9.87 million | $17.58 million | $34.22 million | $63.82 million |
| Net Loss | $(7.14) million | $(15.18) million | $(26.75) million | $(47.18) million |
| Net Loss Per Share (Basic/Diluted) | $(3.72) | $(7.93) | $(13.94) | $(24.73) |
| Cash & Cash Equivalents | $17.75 million | $9.37 million | $17.75 million | $9.37 million |
| Short-term Investments | $14.16 million | $29.17 million | $14.16 million | $29.17 million |
| Long-term Investments | $6.91 million | $33.82 million | $6.91 million | $33.82 million |
| Total Liquidity (Cash + Investments) | $38.82 million | $72.36 million | $38.82 million | $72.36 million |
| Accumulated Deficit | $(454.15) million | $(411.47) million | $(454.15) million | $(411.47) million |
Note: All figures in millions unless otherwise noted. Liquidity includes cash, cash equivalents, short-term, and long-term investments.
Material Changes vs. Prior Period
- Expense Reduction: Operating expenses decreased significantly year-over-year. For the nine months ended September 30, 2025, total operating expenses dropped by $29.6 million compared to the same period in 2024. This was driven by a 50% workforce reduction announced in May 2024 and the discontinuation of the trastuzumab imbotolimod (BDC-1001) program.
- Revenue Fluctuation: While Q3 2025 revenue increased by $1.0 million compared to Q3 2024 (due to Genmab services), YTD revenue decreased by $2.5 million. The YTD decline is primarily attributed to the recognition of revenue under the Amended Innovent Agreement in 2024, which was recognized as a one-time event and did not recur in 2025.
- Investment Portfolio: Total marketable securities decreased from $62.9 million at year-end 2024 to $21.1 million at September 30, 2025, reflecting maturities and purchases to manage cash flow.
- Reverse Stock Split: A 1-for-20 reverse stock split was effected on June 6, 2025. All share and per-share data in this filing have been retrospectively adjusted.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern within one year of the issuance of these financial statements. While current liquidity ($38.8 million) is projected to fund operations into 2027, this relies heavily on uncertain collaboration income. Additional capital will be required.
- Recent Restructuring (Subsequent Event): On October 1, 2025, the company announced a new restructuring plan to reduce the workforce by approximately 50% (approx. 20 employees). Estimated pre-tax charges of $1.5 million to $2.0 million are expected to be recorded in Q4 2025.
- Pipeline Focus: The company is prioritizing BDC-4182 (Claudin 18.2 ISAC) and BDC-3042 (Dectin-2 agonist). BDC-3042 is not in active development and is available for partnering.
- Risk Factors: Key risks include the need for substantial additional funding, reliance on third-party manufacturers (some located in China and South Korea), potential impacts of new U.S. tariffs and trade policies, and the uncertainty of clinical trial outcomes.
- Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 is not expected to materially impact the company's financial statements.
Investor Verification Checklist
- Cash Runway Validation: Verify the assumptions regarding collaboration revenue (Toray and Genmab) used to project funding into 2027, given the "substantial doubt" disclosure.
- Restructuring Impact: Monitor Q4 2025 results for the actual costs of the October 2025 workforce reduction and its effect on the burn rate.
- Collaboration Milestones: Review the status of the Genmab and Toray agreements to ensure continued revenue recognition and potential for future milestone payments.
- Capital Raising: Assess the company's strategy for raising additional capital, as equity dilution or unfavorable debt terms may be necessary if partnerships do not materialize.
- Supply Chain Exposure: Evaluate the specific risks associated with reliance on single-source manufacturers in regions subject to potential trade tariffs or geopolitical instability.